Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Thoratec Corp Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance


Wednesday, 31 Jul 2013 04:02pm EDT 

Thoratec Corp reaffirmed prior guidance for fiscal 2013 revenues, which are expected to be in the range of $490 million to $510 million. For fiscal 2013 net income per share, the Company has adjusted its GAAP and non-GAAP guidance to account for the previously disclosed $6-7 million of recurring operating expenses (approximately $0.07 per share on an after-tax basis) associated with the development of DuraHeart II, which Thoratec recently acquired. GAAP net income per share guidance has also been adjusted to include $1.3 million of transaction-related expenses incurred through the end of the second quarter. Following these adjustments, GAAP net income per diluted share is expected to be in the range of $1.23 to $1.33, and non-GAAP net income per diluted share is expected to be in the range of $1.69 to $1.79. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $495 million, EPS of $1.75 for fiscal 2013. 

Company Quote

63.22
0.6 +0.96%
17 Apr 2014